Ivor Macleod CPA, M.B.A. Net Worth

The estimated Net Worth of Ivor Macleod is at least $602 millier dollars as of 17 November 2021. Mr Macleod owns over 15,000 units of Athersys Inc stock worth over $14,922 and over the last 5 years he sold ATHX stock worth over $0. In addition, he makes $587,214 as Chief Financial Officer & Principal Accounting Officer at Athersys Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr A ATHX stock SEC Form 4 insiders trading

Mr has made over 1 trades of the Athersys Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 15,000 units of ATHX stock worth $17,700 on 17 November 2021.

The largest trade he's ever made was buying 15,000 units of Athersys Inc stock on 17 November 2021 worth over $17,700. On average, Mr trades about 1,500 units every 0 days since 2020. As of 17 November 2021 he still owns at least 146,583 units of Athersys Inc stock.

You can see the complete history of Mr Macleod stock trades at the bottom of the page.

Mr. Ivor Macleod CPA, M.B.A. biography

Ivor Macleod CPA, M.B.A. is the Chief Financial Officer & Principal Accounting Officer at Athersys Inc.

What is the salary of Mr A?

As the Chief Financial Officer & Principal Accounting Officer of Athersys Inc, the total compensation of Mr A at Athersys Inc is $587,214. There are 4 executives at Athersys Inc getting paid more, with Gil Van Bokkelen having the highest compensation of $1,596,650.

How old is Mr A?

Mr A is 59, he's been the Chief Financial Officer & Principal Accounting Officer of Athersys Inc since . There are 4 older and 9 younger executives at Athersys Inc. The oldest executive at Athersys Inc is Lorin Randall, 76, who is the Independent Director.

Insiders trading at Athersys Inc

Over the last 17 years, insiders at Athersys Inc have traded over $3,715,462 worth of Athersys Inc stock and bought 2,242,389 units worth $3,620,264 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Michael B Sheffery et Jordan Davis. On average, Athersys Inc executives and independent directors trade stock every 43 days with the average trade being worth of $3,231. The most recent stock trade was executed by Daniel A. Camardo on 22 November 2022, trading 100,000 units of ATHX stock currently worth $55,000.

What does Athersys Inc do?

athersys is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics to treat significant and life-threatening diseases. we are engaged in the discovery and development of innovative new medicines designed to extend and enhance the quality of human life. through the application of our proprietary technologies, we have established a pipeline of therapeutic product development programs in multiple disease areas. this pipeline includes both stem cell therapy and pharmaceuticals.

Complete history of Mr Macleod stock trades at Athersys Inc et Scynexis Inc

Athersys Inc executives and stock owners

Athersys Inc executives and other stock owners filed with the SEC include:

• Gil Van Bokkelen,
  Chairman of the Board, Chief Executive Officer
• John Harrington,
  Executive Vice President, Chief Scientific Officer, Director
• William Lehmann,
  President, Chief Operating Officer
• Laura Campbell,
  Senior Vice President - Finance
• Ivor Macleod CPA, M.B.A.,
  Chief Financial Officer & Principal Accounting Officer
• Dr. John J. Harrington,
  Co-Founder, Chief Scientific Officer, Exec. VP & Director
• William B. J. Lehmann Jr., M.B.A., J.D., MBA,
  Pres, COO, Sec. & Interim CEO
• Lorin Randall,
  Independent Director
• Jack Wyszomierski,
  Independent Director
• Ismail Kola,
  Independent Director
• Jane Wasman,
  Director
• Baiju Shah,
  Director
• Katherine Kalin,
  Director
• Hardy Kagimoto,
  Director
• Maia Hansen,
  Senior Vice President - Operations, Supply Chain
• Ivor Macleod,
  Chief Financial Officer
• Dr. Eric Jenkins M.D.,
  Sr. Medical Director & Head of Clinical Operations
• Maia Hansen M.B.A., M.S.,
  Sr. VP and Head of Operations & Supply Chain
• Rakesh Ramachandran,
  Head of Information Technology & Communications and VP
• Dr. Robert Mays Ph.D.,
  VP of Regenerative Medicine & Head of Neuroscience Programs
• Dr. Manal Morsy M.D., PH.D.,
  Sr. VP & Head of Global Regulatory Affairs
• Alison O'Sullivan M.B.A.,
  Sr. Director of HR
• Karen Hunady M.S.,
  Director of Corp. Communications & Investor Relations
• Jordan Davis,
  Director
• Lee Babiss,
  Director
• Neema Mayhugh,
  Director
• Joseph Patrick Nolan,
  Director
• K.K. Healios,
  
• Tadahisa Kagimoto,
  Director
• Robert J Deans,
  Sr. Vice President
• Kenneth Traub,
  Director
• Advisors Llc Orbi Med Capit...,
  
• George M Jr Milne,
  Director
• Floyd D Md Loop,
  Director
• Advisors Llcisaly Samuel D ...,
  
• Michael B Sheffery,
  Director
• William C Mulligan,
  Director
• Daniel A. Camardo,
  CEO